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TauAlzheimer's disease is the most devastating neurodegenerative disorder in the elderly, yet treatment options
are severely limited. The drug development effort to modify Alzheimer's disease pathology by intervention at
beta amyloid production sites has been largely ineffective or inconclusive. The greatest challenge has been to
identify and deﬁne downstream mechanisms reliably predictive of clinical symptoms. Beta amyloid accumu-
lation leads to dysregulation of intracellular calcium by plasma membrane L-type calcium channels located
on neuronal somatodendrites and axons in the hippocampus and cortex. Paradoxically, L-type calcium chan-
nel subtype Cav1.2 also promotes synaptic plasticity and spatial memory. Increased intracellular calcium
modulates amyloid precursor protein processing and affects multiple downstream pathways including in-
creased hyperphosphorylated tau and suppression of autophagy. Isradipine is a Federal Drug Administra-
tion-approved dihydropyridine calcium channel blocker that binds selectively to Cav1.2 in the
hippocampus. Our studies have shown that isradipine in vitro attenuates beta amyloid oligomer toxicity by
suppressing calcium inﬂux into cytoplasm and by suppressing Cav1.2 expression. We have previously
shown that administration of isradipine to triple transgenic animal model for Alzheimer's disease was
well-tolerated. Our results further suggest that isradipine became bioavailable, lowered tau burden, and im-
proved autophagy function in the brain. A better understanding of brain pharmacokinetics of calcium channel
blockers will be critical for designing new experiments with appropriate drug doses in any future clinical tri-
als for Alzheimer's disease. This review highlights the importance of Cav1.2 channel overexpression, the ac-
cumulation of hyperphosphorylated tau and suppression of autophagy in Alzheimer's disease and
modulation of this pathway by isradipine.y Mail Code: R&D 67 Oregon
oad Portland, OR 97239, USA.
).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Beta amyloid (Aβ plaque in Alzheimer's disease (AD)) accumu-
lates long before patients become symptomatic; therefore, many
therapeutic efforts have now moved to very early intervention. An-
other strategy to tackle the discordance between Aβ production and
AD symptoms is to target mechanisms of neurodegeneration which
are “downstream” of Aβ production. The greatest challenge has
been to identify critical pathways that directly impact clinical symp-
toms and then effectively modulate these pathways by pharmacolog-
ical agents. We and others have observed that a speciﬁc set of
downstream pathways including dysregulation of intracellular calci-
um (Ca2+), upregulation of caspase-cleaved tau (tau-C3), hyperpho-
sphorylation of tau (ptau), and loss of cellular housekeeping orautophagy function, may contribute directly to the expression of clin-
ical symptoms. Multiple mechanisms control these seemingly unre-
lated pathways. A vast amount of current literature substantiates
their critical but complex role in AD pathology [1–12].
1.1. Calcium trafﬁcking is a complex process
Ca2+ trafﬁcking is a complex process. A tight functional link exists
among channels located on the plasma membrane (Aβ pores; L-type
calcium channels, LTCC; N-methyl D-aspartyl receptor, NMDAR), en-
doplasmic reticulum (ryanodine receptor, RyR; Inositol(1,4,5)P3
receptor, InsP3R; sarco endoplasmic reticulum calcium ATPase,
SERCA), and mitochondria [13–16]. Further, presenilin proteins, in-
volved in AD pathogenesis, are located on the ER and can leak Ca2+
into the cytoplasm or interact with RyR, InsP3R, and SERCA to increase
their activity [9,12,17]. A P86L polymorphism in a novel calcium
channel called calcium homeostasis modulator 1 (CALHM1) can inﬂu-
ence Aβ production by modulating amyloid precursor protein (APP)
processing [11,12]. Such a complexity involving a bidirectional rela-
tionship between Aβ production and calcium homeostasis pathways
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Recent publications in the triple transgenic mouse model of AD
(3xTgAD) implicate roles of RyR, InsP3R and NMDAR in the produc-
tion of Ca2+ and synaptic plasticity of hippocampal neurons
[18–21], but the role of LTCC, especially of Cav1.2, in relation to Aβ,
tau, and autophagy is largely unknown. Therefore, in this review,
we mainly focus on Cav1.2 relationship to AD pathology.
1.2. L-type calcium channel subtype Cav1.2 is a critical target for calcium
channel blockers in AD brains
Aging and Aβ consistently promote Ca2+ inﬂux into neurons by
way of L-type calcium channels (LTCCs). Soluble intraneuronal Aβ
oligomers, soluble and insoluble Aβ ﬁbrils can increase intracellular
Ca2+, impair neuronal function, and adversely affect synaptic func-
tions in AD [13,22,23]. Ca2+ increase occurs through overactivation
of LTCCs [24]. The uncontrolled Ca2+ increase can trigger the overex-
pression of plasma membrane LTCC subtype Cav1.2 in the hippocam-
pus of AD brains and further exacerbate the pathogenic Ca2+ inﬂux
[1,25,26]. Cav1.2 is located in cell bodies and dendrites, axonal termi-
nals, and axons of neurons, and glial processes of the hippocampus
[2]. Paradoxically, Cav1.2 expression is essential for long-term poten-
tiation (LTP) (independent of NMDAR-dependent LTP), synaptic plas-
ticity, and spatial memory of the hippocampus [1,2]. Cav1.2KO in mice
disrupts remote spatial memory, further conﬁrming the importance
of Cav1.2 [1]. Cav1.3, a closely-related LTCC subtype known to mediate
the pace-making function of dopaminergic neurons in Parkinson's
disease, has no known role in hippocampal memory function [27,28].
Our recent study has examined the role of Cav1.2 in response to
intracellular oligomeric Aβ because such understanding is an emerg-
ing area of relevance to AD [29]. Cav1.2 channel expression is essentialFig. 1. A schematic overview of the Aβ–Cav1.2–ptau–autophagy pathway. Three sections of
insoluble Aβ ﬁbrils generated from amyloid precursor protein (APP) processing cause increa
or other unknown pathways (Section 1). Aβ production can be directly modulated by muta
plasmic reticulum, or in response to treatment with dihydropyridine (DHP) class of calcium
expression of Cav1.2, increased inﬂux of Ca2, disrupted autophagy, and up-regulated ptau ex
autophagy function. Pathological accumulation of autophagosomal vacuoles and ptau will le
block this pathway.for long-term potentiation (LTP) independent of NMDAR-dependent
LTP, synaptic plasticity, and spatial memory of the hippocampus [1–
3,5,18,28]. Multiple pathways involving generation of intraneuronal
or soluble extracellular Aβ can induce protein kinase A (PKA),
which in turn binds to LTCC and promotes increased Ca2+ inﬂux
[30,31]. PKA binding to the alpha subunit of Cav1.2 in the cytoplasm
causes Cav1.2 overexpression in the membrane [30,31]. PKA also pro-
motes pathological hyperphosphorylation of tau [32,33] and suppres-
sion of autophagy function in AD [34] (Fig. 1; Sections 1 and 3).
It is important to recognize that Cav1.2-independent pathways
may also directly inﬂuence Aβ production, ptau or autophagy func-
tions. Aβ-toxicity that is independent of Cav1.2 may occur when
intraneuronal Aβ directly enters mitochondria and disrupts cellular
energy balance or promotes free radical production [35]. Alternative-
ly, free radicals can be generated from APP in autophagosomal com-
partments and disrupt autophagy function without affecting Cav1.2
[36].
1.3. Autophagy dysfunction in AD
The emerging literature suggests that autophagy, a self-cleaning
cellular housekeeping mechanism, plays an important role in AD pa-
thology [36]. Previously, it was assumed that autophagy was induc-
ible only in response to stress but not essential for cell function. The
most recent literature, however, provides unequivocal evidence for
the constitutive role of autophagy in cellular homeostasis, thus mak-
ing it essential for neuronal survival [37,38]. Autophagosomal vacu-
oles accumulate in AD [7,36,39,40], which can lead to an accelerated
accumulation of ptau and tau-C3 [41–43]. Accumulated ptau, in
turn, can rupture lysosomes, causing them to prematurely release
proteolytic enzymes into the cytoplasm and disrupt normalthe ﬁgure are separated by dashed lines for clarity. Soluble Aβ oligomers, soluble and
sed expression of Cav1.2 through beta 2 adrenergic receptor (β2AR)/cyclin AMP (cAMP)
tions in the calcium homeostasis modulator 1 (CALHM1) receptor located on the endo-
channel blockers (CCBs) (Section 2). Intracellular or extracellular Aβ can cause over-
pression (Section 3). Ca2+–calpain pathway can directly increase ptau levels or dampen
ad to loss of spatial memory and cognition in AD (Section 3). Isradipine (ISR) appears to
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[44–46]. A heterozygous deletion of the autophagy marker beclin-1
in Tg2576 mice increases intraneuronal Aβ accumulation, extracellu-
lar Aβ deposits, and neurodegeneration [47], suggesting that autop-
hagy plays a key protective role against AD. Autophagy function is
suppressed in several mouse models including 3xTgAD [48–50]. In-
deed one of the main functions of autophagy is to regulate mitochon-
drial function by enzymatic degradation of dysfunctional
mitochondria and by clearing misfolded proteins in the cell [41,51].
Our studies in Tg2576 mice provide strong evidence for mitochondri-
al deposition of Aβ leading to generation of free radicals and a pro-
tective role of autophagy against AD pathology [35].
1.4. Caspase-cleaved and hyperphosphorylated tau
A considerable effort has beenmade in the past few decades to un-
derstand tau-associated pathology in AD [52–55]. There seems to be a
general consensus among experts that: (1) hyperphosphorylated tau
appears early in the disease progression and is more prone to aggre-
gation and tangle formation than the normal tau [52,56,57]. Increased
Ca2+ can promote ptau via calpain-dependent pathway [58,59]; (2)
the presence of more 3-repeat tau conformations relative to 4-repeats
can be pathogenic in AD [55,60]; and (3) caspase-cleaved tau-C3 is
ﬁbrillogenic with much greater propensity for aggregation and for-
mation of ptau and neuroﬁbrillary tangles [53,61,62]. The most excit-
ing and numerous roles of tau-C3 in AD pathology are still emerging
in the literature. When wild type tau is cleaved mainly by caspase-3
at Asp421 site, a tau-C3 is formed [56,62]. A recent study suggests
that caspase activation may precede tangle formation in tau transgen-
ic Tg4510 mice [63]. Some suggest that tau-C3 is present in tauopa-
thies in the absence of Aβ pathology [43]. Lysosomal dysfunction
may promote the increased formation of tau-C3 [44]. Thus, these
emerging studies strongly suggest that the clearance pathway of
tau-C3 is tightly linked to autophagy–lysosomal pathways in AD. Fur-
thermore, tau-C3 is preferentially degraded by the macroautophagy
pathway [41]. Ca2+ toxicity or overexpression of Cav1.2 can also
lead to mislocalization of tau into somatodendritic regions instead
of normal axonal localization [64]. In somatodendritic regions, tau
can damage microtubules and spines and become ptau [64].
These studies together provide a strong evidence for complex
roles of Aβ, Cav1.2, Cai2+, tau-C3, ptau, autophagy–lysosomal dysfunc-
tion in orchestrating AD pathology. We call this nexus of toxicity in
short: Aβ–Cav1.2–ptau–autophagy pathway.
2. Calcium channel blockers to break the nexus of toxicity
Usefulness of LTCC blockers (CCBs) against AD pathology is con-
troversial. Epidemiological studies suggest that CCBs prevent [65] or
slow the rate of progression of AD [66,67]. A large clinical trial with
nimodipine did not show signiﬁcant beneﬁts from the primary out-
come measures but has shown moderate beneﬁts for treatment of
AD in the secondary outcome measures [68,69]. In a recent study,
however, nimodipine selectively stimulated the secretion of Aβ1–42
in vitro and in the plasma of Tg2576 mouse model of AD, questioning
the usefulness of this CCB for AD [70]. Several clinical studies have
suggested that CCBs used as antihypertensive drugs may prevent cog-
nitive decline in hypertensive subjects [71–74], but none has demon-
strated a role for CCBs in AD per se. Two dihydropyridine CCBs were
among the eight FDA-approved drugs selected from 485 small bio-
molecules screened for their ability to induce autophagy without
causing toxic effects in human neuroglioma H4 cells [75]. Further,
dihydropyridine-based derivatives act as potent activators of anti-
aging neuroprotective protein sirtuin 1 [76], which appears to regu-
late autophagy function [77].
Two recent in vitro studies have shown usefulness of DHP CCBs on
Aβ production and Aβ1–42 transcytosis across an in vitro blood–brainbarrier (BBB) created by an apical “blood” and basolateral “brain”
layers of human brain microvascular endothelial cells [78,79]. Nilva-
dipine, nitrendipine, and amlodipine reduced Aβ production in 7W
Chinese hamster ovary (CHO) cells, which have been stably trans-
fected with human APP751 [79]. This study further shows an im-
proved Aβ clearance by nilvadipine and nitrendipine, and an
improved explorative activity for animals treated with nilvadipine
in a transgenic animal model of AD (Tg PS1/APPsw) [79]. The BBB
transcytosis of Aβ1–42 also increased for several of DHP CCBs includ-
ing nitrendipine, nicardipine, nimodipine, and nilvadipine [78]. In
their study, isradipine had no effect on Aβ1–42 transcytosis. Further-
more, CCBs (nitrendipine, cilnidipine, nilvadipine) promoted Aβ1–42
clearance across the BBB in wild type mice; and in animals treated
with human Aβ1–42, nilvadipine improved the cognitive functions of
the animals in Morris water maze test [78]. These studies clearly sug-
gest that DHP CCBs possess non-channeling functions that are inde-
pendent of their calcium channel blocking ability, suggesting a need
for thorough validation of CCBs for AD.
2.1. Why isradipine a suitable CCB for treatment of AD?
Emerging studies in models of Parkinson's disease (PD) show neu-
roprotection by isradipine, an FDA-approved dihydropyridine class of
CCB for hypertension [27,80–82]. In these studies, isradipine blocks
LTCC subtype Cav1.3 function in dopaminergic neuron of the substan-
tia nigra and modulates autonomous pacemaking function [27,82,83].
Isradipine provides protection against stroke and brain ischemia in
rat models for hypertension [84,85]. Early studies focusing on binding
properties of [3H]isradipine in AD and control brains suggest that the
hippocampal CA1 region experiences greater cell loss in response to
increased expression of LTCCs in AD brains relative to control brains
[86,87], suggesting that isradipine treatment is likely to modulate
the over-expressing LTCCs in the CA1 region and preserve the hippo-
campal function. Isradipine can also attenuate over active LTCC func-
tion as well as oxidative stress-induced apoptotic cell death in
hypobaric hypoxia model of rats and preserve their memory function
[88]. Our preliminary studies have clearly shown the superior effects
of isradipine over nimodipine in vitro [29]. We also predict that the
brain bioavailability of therapeutic doses of isradipine is superior to
that of nimodipine, as bioavailability studies in animals generally sup-
port this assertion [89,90].
A recent isradipine safety and tolerability study in PD provides
valuable guidelines on how to evaluate the neuroprotective effects
of isradipine in clinical trials [80]. In this study, subjects (average
age=~59 years) with early PD were treated with increasing doses
of controlled release isradipine (5–20 mg daily doses) over a period
of eight weeks. There was a dose-dependent tolerability for isradipine
(94% for 5 mg; 87% for 10 mg; 68% for 15 mg; 52% for 20 mg). Isradi-
pine did not show any signiﬁcant impact on blood pressure or motor
disability, but leg edema and dizziness were the two frequent adverse
symptoms commonly observed in this study, leading to a conclusion
that 10 mg daily dose of isradipine was a safe treatment [80]. In a
Danish case–control study (average age=72 years), the effect of
DHP class of CCBs was evaluated retrospectively for their neuropro-
tective effects on PD [27]. The commonly prescribed centrally-acting
DHP CCBs (nimodipine, isradipine, nitrendipine, nifedipine), as op-
posed to non-DHP class of CCBs, provided up to 27% risk reduction
for PD, irrespective of treatment length and duration [27]. These stud-
ies appear to suggest that careful clinical trials using isradipine in
older patients are highly feasible, safe, and unlikely to cause adverse
effects on the memory-related function of Cav1.2.
2.1.1. In vitro studies
Our recent publication is the ﬁrst such report to show neuropro-
tection of isradipine against Aβ-induced Ca2+ toxicity in human neu-
roblastoma/MC65 cells [29]. MC65 cells that are stably transfected
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ment of the amino-17 and carboxyl-99 residues [91,92]. APP–C99
gene expression in these cells is controlled by a tetracycline-respon-
sive promoter whose activity is repressed in the presence of tetracy-
cline or induced by withdrawing tetracycline from the growth
medium. Removal of tetracycline leads to expression of the C-termi-
nal APP fragment and subsequent processing of this fragment into
Aβ monomers followed by accumulation of intracellular Aβ oligo-
mers, and precipitous cell death by about 72 h. In this cell culture
model we tested the role of Cav1.2 expression on Cai2+ inﬂux and
cell survival as well as protective effects of four CCBs (diltiazem, ve-
rapamil, nimodipine, isradipine) against Cai2+-induced toxicity. Isra-
dipine was the most potent of the four CCBs tested [29]. This study
suggests that intracellular Aβ oligomers trigger increased intracellu-
lar Ca2+ inﬂux primarily through Cav1.2 channels. None of these
CCBs prevented the formation of intracellular oligomers. Isradipine
provided protection against Ca2+ toxicity by both blocking calcium
inﬂux and suppressing Cav1.2 expression downstream of Aβ forma-
tion [29]. Our study results also indicate that Ca2+ levels are tightly
controlled and cells respond to small variations in Ca2+ and this re-
sponse is sensitive to small concentrations of isradipine [29].
2.1.2. In vivo studies
We also tested isradipine for its neuroprotective functions in four
evolutionarily divergent species including models for AD: human
neuroblastoma/MC65 cells, transgenic Drosophila, Monduca, and
3xTgAD mice [93]. In transgenic Drosophila model, 250 μM isradipine
increased the survival of ﬂies from 6.5% to 12% (pb0.5) against APP695
toxicity [93]. In moth/Monduca sexta experiments, embryonic culture
preparations were exposed to exogenous Aβ1–42 peptide to deter-
mine the toxic effects of this peptide on neuronal development and
growth in the presence or absence of 10 μM isradipine [93]. Treat-
ment with Aβ1–42 induces concentration-dependent perturbations
in the extent of migration and outgrowth of enteric nervous system.
A simultaneous treatment with isradipine prevents the deleterious
effects of Aβ [93]. Our studies further show that subcutaneous ad-
ministration of isradipine (3 μg/g/day; 60-day release) to 3xTgAD
mice was well-tolerated and isradipine became available to the
brain [29,93]. The 3xTgAD mouse model, which harbors PS1
(M146V), APPswe and tau (P301L) transgenes, develops age-depen-
dent and region-speciﬁc Aβ and tau aggregations in the cortex and
hippocampus that closely mimics the pathology found in human AD
[94,95]. A small cohort of 17-month-old female 3xTgAD mice (an
age well after the appearance of AD pathology) was implanted with
carrier-bound isradipine pellets (n=3, 3 mg/kg/day, 60-day release,
Innovative Research of America) or placebo control pellets (n=4).
Isradipine was well-tolerated as evidenced by average weekly body
weights (an indirect measurement of toxicity), which were the
same for vehicle and isradipine-treated animals. Isradipine treatment
also showed lowering trend for insoluble Aβ1–40 and Aβ1–42, no effect
on soluble Aβ1–40, and undetectable soluble Aβ1–42 [93]. Histological
Aβ burden in these animals reduced non-signiﬁcantly in the hippo-
campus and isradipine signiﬁcantly lowered IHC-detectable ptau bur-
den in the hippocampus [93]. In a second cohort of 22-month-old
female 3xTgAD (N=8) and age-matched wild type (N=8) mice, a
similar isradipine or vehicle pellet implantation showed signiﬁcantly
upregulated LC3B protein, a marker for late-stage autophagy (unpub-
lished results) in isradipine-treated mice. These animal studies to-
gether strongly suggest that protective functions of isradipine are
similarly conserved across evolutionarily divergent species and
these functions are mutually synergistic.
2.2. LTCC blocking with isradipine: implications for future research
Our novel ﬁndings show that isradipine can modulate AD patholo-
gy by inﬂuencing Aβ production upstream as well as components ofthe Cav1.2–ptau–autophagy pathway. This will have much larger im-
plications in developing a unique treatment strategy for AD. Isradipine
appears to bind strongly to Cav1.2 in the hippocampus and perhaps
short-circuits the downstream pathway [3,96,97] (Fig. 1; Section 3).
Mechanisms that promote the clearance of rapidly cluttering autopha-
gosomal vacuoles in AD brains have been elusive for the past several
decades, and they now appear to be an important bottleneck in mov-
ing forward with effective treatment strategies for AD. Fortunately,
calcium channel blockers are emerging as modulators of autophagy
function [75,98]. We believe that an approach to use CCB to short-cir-
cuit the entire downstream pathway can overcome current hurdles in
the clinical treatment of AD.We argue that isradipine is an appropriate
candidate for future studies, as it appears to possess additional func-
tions capable of modulating both upstream and downstream protec-
tive functions besides its calcium channel blocking ability.
Calcium channel blocking will have many implications for future
research and clinical trials: (1) suppression of Cav1.2 expression
through β2AR/cAMP/PKA or mitochondrial PKA-dependent pathways
can defuse the upstream toxic effects of Aβ or reactive oxygen species
[30,31]. (2) PKA-dependent suppression of LC3 function in autophagy
can be neutralized by blocking Cav1.2 [99,100]. (3) Attenuated Ca2+-
dependent calpain levels can downregulate ptau and caspase-cleaved
tau production. It is possible that LTCC blocking may provide effective
protection strategies for Parkinson's disease, Huntington's disease,
ALS, axotomy, brain ischemia, and stroke, where autophagy or isradi-
pine is known to play key protective roles. It is important to recognize
that there may be some risk in modulating Cav1.2 expression speciﬁ-
cally in the hippocampal CA1 pyramidal neurons, since these receptors
also directly inﬂuence long-term potentiation, synaptic plasticity, and
spatial memory function [3,5,28,101]. However, several lines of evi-
dence discussed at the top of this section suggest that isradipine pre-
dominantly modulates Cav1.2 rather than adversely effecting the
memory function associatedwith normal function of Cav1.2 [27,80,86].
3. Bioavailability of calcium channel blockers
In the past three decades, several bioanalytical methods (radio-
active labeling, gas chromatography, high pressure liquid chroma-
tography) have been developed for assessing isradipine
pharmacokinetics and pharmacodynamics in animal and human tis-
sues [6,86,89,90,102,103]. The most important discovery from these
early methods is that isradipine undergoes extensive ﬁrst-pass me-
tabolism and nearly 90% of orally administered isradipine is
absorbed in the digestive tract, limiting its bioavailability to about
17–28% in plasma. For an immediate release (IR) formulation of
isradipine, a sharp peak concentration occurs in plasma about 1.5–
2 h after administration with a terminal half-life of 8 h [89]. Sus-
tained-release (SR) formulations show superior bioavailability with
an initial lag period for 2–3 h and then a slow increase in concentra-
tion reaching a plateau between 7 and 18 h after dosing. Thus, SR
formulation shows a lower maximal plasma concentration (Cmax)
and an extended maximal tissue concentration (Tmax) as well as ex-
tended mean elimination half-life (T½) compared to IR formulation
[89]. However, many of the early methods showed low sensitivity,
longer analytical time, and involved pre-column derivatization pro-
tocols affected by interferences, making them prohibitively expen-
sive for large-scale rapid screening of clinical samples. Recently, a
liquid chromatography coupled to tandem mass spectrometry (LC–
MS/MS) has been developed as sensitive, accurate, and rapid meth-
od for assessment of isradipine bioavailability in the plasma samples
from healthy volunteers [104]. This method showed an excellent
linearity between 10 and 5000 pg/ml of isradipine in plasma, with
the lower limit of quantitation (LLOQ) at 10 pg/ml plasma and a
short retention time [104]. We have recently applied this method
successfully to a 3xTgAD mice [29]. In our studies with 3xTgAD
mice, we detected 33±7 ng/ml of isradipine in the plasma and
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bound isradipine pellets (3 μg/g/day, 60-day release, Innovative Re-
search of America, Sarasota, FL) and none in animals implanted
with placebo control pellets [29].
To be able to apply the above method to AD patients, we need to
establish relationships between plasma and brain bioavailability of
isradipine ﬁrst in animal models of AD. This approach needs some
practical considerations. First, there is a possibility that the plasma-
to-brain relationship for isradipine may be a non-linear function. Be-
cause isradipine can easily cross the blood–brain barrier [105], we ex-
pect isradipine will reach the brain readily. Thus the non-linearity
argument may be somewhat muted. Second, there is a possibility
that Tmax and T½ for isradipine may differ from mouse to human. In-
terestingly, cross-species pharmacokinetics appears to be remarkably
comparable between mouse and human, including for isradipine
[89,103,106]. So, these parameters are expected to remain similar in
mouse and human brains; thus, information obtained on mouse
models can be easily translatable to humans. Third, transgenic animal
models do not fully account for the genetic heterogeneity prevalent in
the late-onset AD population. This is a serious issue and one way to
maximize heterogeneity in animal populations is by using different
genotypes/animal models and age groups. Alternatively, pharmacoki-
netic measures such as area under curve (AUC) can be determined for
plasma and brain to ensure a greater accuracy. Such an approach will
require multiple time points of measurements after isradipine dosing
and will increase the number of animals required for the study. In live
humans, brain function or cerebrospinal ﬂuid levels rather that brain
levels of isradipine can be modeled with plasma levels of isradipine to
develop clinically useful predictive functions.
4. Conclusions
Despite their long-standing presence and well-deﬁned safety re-
cords, the usefulness of CCBs for Alzheimer's disease has been unclear.
The reluctance to use CCBs to ADmay be attributed to the initial failure
of nimodipine in an AD clinical trial. However, recent experimental ev-
idence presented in this review demonstrates that CCBs such as isradi-
pine possess multiple beneﬁcial effects besides their primary L-type
calcium blocking ability. Rigorous, well-designed pre-clinical and clin-
ical studies are expected to provide proof-of-concept on the effective-
ness of CCBs for treatment of Alzheimer's disease.
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